Structure Therapeutics Inc. (NASDAQ:GPCR - Get Free Report)'s stock price hit a new 52-week low during mid-day trading on Tuesday . The company traded as low as $22.33 and last traded at $22.68, with a volume of 849610 shares trading hands. The stock had previously closed at $24.39.
Analysts Set New Price Targets
A number of research analysts recently issued reports on GPCR shares. Stifel Nicolaus initiated coverage on Structure Therapeutics in a research note on Wednesday, January 8th. They set a "buy" rating and a $50.00 price objective for the company. JMP Securities restated a "market outperform" rating and issued a $91.00 price target on shares of Structure Therapeutics in a research note on Wednesday, December 18th. Finally, HC Wainwright restated a "buy" rating and issued a $80.00 price target on shares of Structure Therapeutics in a research note on Thursday, December 19th. Eight investment analysts have rated the stock with a buy rating, According to MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus target price of $81.29.
Read Our Latest Stock Analysis on GPCR
Structure Therapeutics Stock Performance
The firm has a market capitalization of $1.36 billion, a PE ratio of -32.02 and a beta of -2.75. The company has a fifty day moving average price of $27.52 and a 200-day moving average price of $34.11.
Institutional Trading of Structure Therapeutics
Hedge funds have recently modified their holdings of the company. Spire Wealth Management purchased a new stake in shares of Structure Therapeutics during the 4th quarter worth approximately $243,000. JPMorgan Chase & Co. raised its holdings in Structure Therapeutics by 302.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 33,936 shares of the company's stock valued at $1,489,000 after buying an additional 25,500 shares during the period. Vestal Point Capital LP raised its holdings in Structure Therapeutics by 105.4% during the 3rd quarter. Vestal Point Capital LP now owns 1,150,000 shares of the company's stock valued at $50,474,000 after buying an additional 590,000 shares during the period. abrdn plc raised its holdings in Structure Therapeutics by 132.7% during the 3rd quarter. abrdn plc now owns 217,083 shares of the company's stock valued at $9,528,000 after buying an additional 123,789 shares during the period. Finally, Barclays PLC raised its holdings in Structure Therapeutics by 64.5% during the 3rd quarter. Barclays PLC now owns 81,138 shares of the company's stock valued at $3,562,000 after buying an additional 31,815 shares during the period. 91.78% of the stock is owned by hedge funds and other institutional investors.
About Structure Therapeutics
(
Get Free Report)
Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.
Featured Articles
Before you consider Structure Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Structure Therapeutics wasn't on the list.
While Structure Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
